PAREXEL operates in many of the emerging regions "Hot Spots," such as Latin America, Japan, Central & Eastern Europe, and Asia Pacific. In the last year there has been a 30% increase in clinical trials, which continues to increase dramatically. Also, the worldwide pharmaceutical market is projected to generate well over $1 trillion in revenues by 2012. There are numerous benefits associated with conducting clinical trials in each of these emerging regions. One major advantage is cost savings as R&D is becoming increasingly expensive, it could potentially cost over $1.2 billion to develop a new drug in more traditional markets. Another benefit is that it could take less time to get your drug to market versus in more conventional markets where it could take up to 15 years to commercialize your product.
Total: 60,036 Studies in 157 Countries
Click Image to Enlarge
PAREXEL has developed significant expertise to assist clients in the global pharmaceutical, biotechnology, and medical device industries with the development and launch of their products in order to bring safe and effective treatments to the marketplace for the patients who need them.
Click Image to Enlarge
Regional distribution of trial types as of April 12, 2007 (in percent)
Click Image to Enlarge
Types of trials by region as of April 12, 2008 (in percent)
Click Image to Enlarge
